30 Leading Next-Generation Sequencing Companies Powering Market Growth and Technological Advances

Discover the top 30 companies driving innovation in the Next-Generation Sequencing (NGS) market. This in-depth analysis highlights competitive advantages, transformative technologies, and key players shaping the future of global genomics and precision medicine through 2030. Download the PDF brochure of the Next-Generation Sequencing market and access the comprehensive market research report from MarketsandMarkets for deeper insights.

Spotlights on the Industry's Top Next-Generation Sequencing Companies

The next-generation sequencing market is advancing at an extraordinary pace, driven by the continued decline in sequencing costs, the maturation of long-read and single-cell technologies, the rapid expansion of clinical genomics applications, and the integration of AI-driven bioinformatics into sequencing data interpretation. Valued at USD 13.95 billion in 2024 and reaching USD 14.94 billion in 2025, the global NGS market is projected to grow at a CAGR of 14.6% to reach USD 29.53 billion by 2030. This remarkable trajectory reflects the central and expanding role of genomic sequencing in oncology diagnostics, rare disease identification, infectious disease surveillance, reproductive health, agricultural genomics, and drug discovery. In this dynamic environment, the following 30 industry leaders stand out for their technological innovation, commercial reach, and transformative contributions to the science and application of next-generation sequencing worldwide.

1. Illumina, Inc.

Illumina, Inc. is the defining force in the next-generation sequencing industry, commanding the majority of the global sequencing market through its industry-standard short-read sequencing platforms including the NovaSeq X, NextSeq, and MiSeq series. Illumina's sequencing-by-synthesis chemistry has become the foundation upon which the modern genomics era was built, enabling landmark projects from the Human Genome Project follow-ons to large-scale population genomics initiatives worldwide. Their continuous investment in lowering the cost per genome, expanding clinical sequencing applications, and integrating AI-driven bioinformatics tools ensures Illumina remains the central platform of choice for research institutions, clinical laboratories, and biopharma organizations globally.

2. Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc. is a comprehensive life science solutions provider with a robust NGS portfolio spanning Ion Torrent sequencing instruments, library preparation reagents, target enrichment panels, and bioinformatics software. Their Applied Biosystems and Invitrogen brands supply a broad range of molecular biology tools that underpin sequencing workflows across oncology, infectious disease, reproductive health, and agricultural genomics applications. Thermo Fisher's vertically integrated supply chain, global commercial footprint, and deep customer relationships across research and clinical markets make them a critical enabler of NGS adoption at scale.

3. Agilent Technologies, Inc.

Agilent Technologies, Inc. brings precision chemistry and genomics expertise to the NGS market through its SureSelect and HaloPlex target enrichment systems, which are widely used to capture specific genomic regions of clinical and research interest prior to sequencing. Their deep knowledge of nucleic acid chemistry, hybridization capture technology, and quality control solutions supports researchers and clinical laboratories seeking to maximize the efficiency and accuracy of targeted sequencing workflows. Agilent's strong presence in oncology panel design, liquid biopsy applications, and whole exome sequencing underscores their essential role in the NGS ecosystem.

4. F. Hoffmann-La Roche Ltd.

1. Hoffmann-La Roche Ltd. participates in the NGS market through its AVENIO and SeqCap target enrichment products, companion diagnostic sequencing assays, and a growing portfolio of clinical genomics solutions developed in partnership with its pharmaceutical and diagnostics divisions. Roche's unique position as both a major pharmaceutical company and a leading in vitro diagnostics manufacturer enables it to integrate sequencing-based companion diagnostics directly into its oncology drug development and clinical care pathways. Their investment in single-molecule and long-read sequencing technologies signals continued ambition to shape the future of clinical genomics.

5. Danaher Corporation

Danaher Corporation brings its powerful operating model and portfolio of life science brands to the NGS space, most prominently through Integrated DNA Technologies (IDT), a leading supplier of custom oligonucleotides, xGen target capture probes, and CRISPR reagents essential to sequencing library preparation and enrichment workflows. Danaher's SCIEX and Leica Biosystems brands further intersect with genomics workflows, while IDT's dominant position in the oligo synthesis and NGS reagent markets provides a durable and highly profitable contribution to the broader sequencing supply chain.

6. QIAGEN

QIAGEN is a global leader in sample and assay technologies whose NGS portfolio encompasses nucleic acid extraction kits, library preparation solutions, targeted panel sequencing systems, and the QIAseq product family designed to optimize sequencing data quality from challenging sample types. Their QIAcuity digital PCR systems and GeneReader NGS platform complement a comprehensive sample-to-insight offering tailored to clinical and translational research environments. QIAGEN's deep expertise in sample quality—the foundational step that determines all downstream sequencing success—makes them an indispensable partner across the NGS workflow.

7. Revvity

Revvity, formerly PerkinElmer's life sciences and diagnostics business, brings a broad suite of genomics, reproductive health, and newborn screening solutions to the NGS market. Their NEXTFLEX library preparation kits and genomics reagent portfolio support high-throughput sequencing workflows in research and clinical laboratories. Revvity's particular strength in newborn screening, prenatal genomics, and rare disease diagnostics positions them as an important contributor to the expanding clinical applications of next-generation sequencing across the reproductive health and pediatric medicine continuum.

8. Eurofins Scientific

Eurofins Scientific is one of the world's largest contract research and testing organizations, with a substantial and growing NGS services business spanning whole genome sequencing, targeted panel testing, microbiome analysis, and genomic data services for pharmaceutical, agricultural, environmental, and clinical customers. Their global laboratory network enables large-scale sequencing projects with rapid turnaround and internationally consistent quality standards. Eurofins' breadth of sequencing service offerings, competitive pricing, and scientific expertise across diverse application domains make them one of the most versatile NGS service providers in the global market.

9. PacBio

PacBio is the pioneer and leading provider of long-read sequencing technology, with its Single Molecule, Real-Time (SMRT) sequencing platform delivering read lengths and accuracy levels that complement and increasingly compete with short-read approaches for complex genomic applications. The Revio and Onso platforms offer highly accurate long-read and short-read sequencing respectively, enabling PacBio to address a broader range of research and clinical applications. PacBio's technology is particularly valued for resolving structural variants, phasing alleles, characterizing repetitive genomic regions, and producing reference-quality genome assemblies that short-read platforms cannot match.

10. Oxford Nanopore Technologies PLC

Oxford Nanopore Technologies PLC has disrupted the sequencing industry with its nanopore-based sequencing technology that enables real-time, ultra-long-read sequencing in instruments ranging from the pocket-sized MinION to the high-throughput PromethION platform. Oxford Nanopore's unique direct sequencing of native DNA and RNA molecules—without amplification—enables detection of base modifications, structural variants, and full-length transcripts with capabilities no other platform currently offers. Their growing presence in clinical pathogen surveillance, cancer genomics, and point-of-care sequencing applications reflects the expanding real-world utility of nanopore technology across scientific and healthcare domains.

11. Takara Bio Inc.

Takara Bio Inc. is a Japanese life science company with a strong NGS product portfolio encompassing library preparation kits, RNA sequencing reagents, single-cell genomics solutions, and SMART-Seq technologies widely used in transcriptomics research. Their SMARTer and SMART-Seq product families have become standard tools for researchers seeking high-sensitivity, low-input RNA sequencing from challenging sample types including single cells and degraded clinical specimens. Takara Bio's deep molecular biology expertise, strong academic research partnerships, and growing global commercial presence position them as a valued reagent and solutions provider in the NGS workflow ecosystem.

12. BGI Group

BGI Group is China's largest genomics organization and a globally significant NGS player, operating through its DNBSEQ sequencing technology platform and its commercial sequencing services arm that processes millions of samples annually for research, clinical, and agricultural customers worldwide. BGI's proprietary DNA nanoball sequencing technology, commercialized through MGI Tech, offers a cost-competitive alternative to established short-read platforms and is gaining international traction. BGI's unmatched scale in sequencing services, population genomics programs, and agricultural genomics makes them one of the most consequential organizations in the global NGS landscape.

13. BD

BD (Becton, Dickinson and Company) contributes to the NGS ecosystem through its Rhapsody single-cell analysis system, which enables high-throughput single-cell transcriptomics and multi-omics profiling integrated with downstream sequencing workflows. Their expertise in cell biology, flow cytometry, and immunology intersects with next-generation sequencing in powerful ways, enabling researchers to characterize immune cell populations, tumor microenvironments, and complex cell communities at single-cell resolution. BD's established global laboratory customer base and clinical diagnostics experience position them as a trusted bridge between single-cell biology and the NGS sequencing workflow.

14. 10x Genomics

10x Genomics has transformed the frontiers of genomics research with its Chromium single-cell sequencing platform, Visium spatial transcriptomics technology, and Xenium in situ analysis system, enabling researchers to explore gene expression, chromatin accessibility, and protein profiling at unprecedented cellular and spatial resolution. Their innovative microfluidics-based sample preparation technologies, combined with powerful analysis software, have made single-cell and spatial genomics accessible to a broad research community. 10x Genomics' rapid expansion of its multi-omics portfolio and growing adoption in translational and clinical research signal a significant and expanding contribution to the future of NGS-enabled biology.

15. Promega Corporation

Promega Corporation is a trusted supplier of molecular biology reagents, including a growing NGS portfolio of library preparation kits, cell-free DNA isolation tools, and methylation analysis solutions supporting epigenomics and liquid biopsy applications. Their Maxwell automated nucleic acid extraction systems streamline sample preparation workflows in both research and clinical settings, ensuring consistently high-quality DNA and RNA inputs for sequencing. Promega's reputation for reagent quality, customer support, and innovation in enzymatic chemistry underpins their relevance as an NGS workflow enablement partner for laboratories worldwide.

16. LGC Limited

LGC Limited is a UK-based life science measurement and testing company with significant NGS contributions through its Biosearch Technologies brand, a leading supplier of oligonucleotides, library preparation reagents, and hybridization capture probes for targeted sequencing applications. Their KAPA Biosystems library preparation chemistry has become one of the most widely adopted and cited NGS library preparation platforms in global research and clinical sequencing laboratories. LGC's quality standards, scientific expertise, and broad genomics reagent portfolio support sequencing laboratories seeking reliable, high-performance molecular tools across diverse application areas.

17. WuXi Biologics

WuXi Biologics, a leading global contract research and manufacturing organization, increasingly intersects with the NGS market through its genomics and bioinformatics capabilities supporting drug discovery, biologics development, and precision medicine programs for its global pharmaceutical and biotech clients. Their genomic sequencing services support target identification, patient stratification, biomarker discovery, and pharmacogenomics research across a growing portfolio of biologic and cell therapy development programs. WuXi's expanding data science and multi-omics infrastructure positions them as an integrated NGS-enabled partner for next-generation drug development.

18. Tecan Trading AG

Tecan Trading AG is a global leader in laboratory automation and liquid handling solutions, whose platforms play an increasingly critical role in scaling and standardizing NGS library preparation and sample processing workflows in high-throughput research and clinical sequencing environments. Their Fluent and Freedom EVO liquid handling workstations automate the precise, repetitive pipetting steps that are essential for consistent NGS library quality at scale. Tecan's deep integration with sequencing instrument ecosystems and their application-specific automation protocols make them an indispensable infrastructure partner for core sequencing facilities and clinical genomics laboratories.

19. Twist Bioscience

Twist Bioscience has pioneered silicon-based DNA synthesis technology that dramatically reduces the cost and increases the scale of synthetic DNA production, enabling a new generation of NGS target enrichment panels, synthetic controls, and gene synthesis products. Their Twist Target Enrichment panels are widely used for whole exome sequencing, custom targeted panels, and liquid biopsy applications, while their synthetic reference standards support sequencing assay validation and quality control. Twist's technological foundation in high-throughput DNA writing positions them as an enabler of the next wave of NGS application innovation, from synthetic biology to clinical diagnostics.

20. Azenta US, Inc.

Azenta US, Inc., operating through its Genewiz brand, is a leading provider of genomics services including Sanger and next-generation sequencing, gene synthesis, and biological sample management solutions for research and biopharma customers globally. Their globally distributed sequencing service laboratories deliver rapid turnaround sequencing for academic, biotechnology, and pharmaceutical researchers spanning whole genome, whole exome, amplicon, and RNA sequencing applications. Azenta's combination of sequencing services expertise, biosample storage capabilities, and cold chain logistics infrastructure makes them a distinctive integrated scientific services partner in the global NGS services market.

21. MGI Tech Co. Ltd.

MGI Tech Co. Ltd., the sequencing instrument and reagent subsidiary of BGI Group, develops and manufactures DNBSEQ-based sequencing platforms that offer a cost-competitive and technically capable alternative to established NGS instrument providers. Their DNBSEQ-G400, DNBSEQ-T7, and MGISEQ platforms serve research institutions, clinical laboratories, and population genomics programs worldwide, with a particular stronghold in Asia and growing international adoption. MGI Tech's aggressive international expansion strategy, competitive instrument pricing, and proprietary consumables supply chain position them as one of the most significant emerging challengers in the global NGS instrument market.

22. Novogene Co., Ltd.

Novogene Co., Ltd. is one of the world's largest NGS services companies, offering whole genome sequencing, transcriptomics, epigenomics, metagenomics, and single-cell sequencing services to research customers across more than 60 countries. Their ultra-high-throughput sequencing centers in China, the UK, the US, and Singapore operate some of the largest clusters of Illumina instruments in the world, enabling massive-scale genomics projects for academic, agricultural, and pharmaceutical research customers. Novogene's combination of scale, bioinformatics expertise, competitive pricing, and broad application coverage makes them a premier genomics services partner for the global research community.

23. New England Biolabs

New England Biolabs (NEB) is a globally trusted supplier of high-quality enzymes, master mixes, and molecular biology reagents, with a growing NGS product portfolio including the NEBNext library preparation kit series that has become a standard tool in sequencing laboratories worldwide. Their deep expertise in enzyme biochemistry, commitment to product quality, and rigorous lot-to-lot consistency have earned NEB an exceptional reputation among research scientists and clinical laboratory professionals. NEB's continued investment in developing novel enzymes and chemistries for library preparation, epigenomics, and sequencing quality enhancement supports their enduring relevance in the rapidly evolving NGS reagent market.

24. GenScript

GenScript is a global biotechnology company offering gene synthesis, molecular biology reagents, and genomics services that intersect significantly with next-generation sequencing workflows and applications. Their gene and oligo synthesis capabilities support the production of synthetic DNA standards, capture probes, and custom constructs widely used in NGS assay development and validation. GenScript's integrated biology services platform—spanning gene to protein to animal model capabilities—positions them as a comprehensive research partner for scientists leveraging NGS as part of broader functional genomics and drug discovery programs.

25. Psomagen

Psomagen is a US-based genomics services company offering whole genome sequencing, microbiome analysis, clinical sequencing, and agricultural genomics services with a focus on delivering high-quality, accessible NGS solutions to research and clinical customers. Their laboratory operations and bioinformatics platforms support diverse application areas including gut microbiome profiling, crop genomics, and clinical oncology panel testing. Psomagen's commitment to analytical quality, competitive service pricing, and responsive customer engagement positions them as a growing provider of specialized NGS services in the North American and global research marketplace.

26. Zymo Research Corporation

Zymo Research Corporation is a California-based life science company renowned for its nucleic acid purification technologies and a growing portfolio of epigenomics and microbiome sequencing solutions built on its proprietary bisulfite conversion and DNA/RNA isolation chemistry. Their Quick-DNA, Quick-RNA, and ZymoBIOMICS product families are widely used to prepare high-quality nucleic acid inputs for NGS workflows, while their DNA methylation sequencing kits support the rapidly expanding field of epigenomic research and clinical epigenetics. Zymo Research's innovation in sample quality and epigenomics sequencing preparation supports the growing demand for multi-dimensional genomic profiling.

27. Hamilton Company

Hamilton Company is a precision liquid handling and laboratory automation specialist whose robotic workstations are widely deployed in high-throughput NGS library preparation, sample normalization, and plate reformatting workflows in core genomics facilities and clinical sequencing laboratories. Their VENUS software ecosystem and application-specific NGS automation methods enable laboratories to achieve consistent, operator-independent sequencing library quality at scale. Hamilton's reputation for precision engineering, flexible automation architecture, and deep application support makes them a preferred automation partner for sequencing centers managing high sample volumes and diverse NGS application workflows.

28. NeoGenomics Laboratories

NeoGenomics Laboratories is a leading US-based oncology testing laboratory with a comprehensive clinical NGS portfolio spanning comprehensive genomic profiling, tumor mutational burden assessment, microsatellite instability testing, and liquid biopsy services for oncologists and biopharma clinical trial programs. Their RaDaR minimal residual disease assay and comprehensive solid tumor and hematologic malignancy sequencing panels support precision oncology treatment decisions and clinical trial patient stratification. NeoGenomics' dedicated clinical focus, CAP/CLIA-certified laboratory operations, and deep oncology expertise position them as a premier clinical NGS testing partner for the oncology community.

29. Fulgent Genetics

Fulgent Genetics is a technology-driven clinical genomics company offering a broad menu of NGS-based diagnostic tests spanning hereditary cancer, rare disease, reproductive health, and infectious disease applications, complemented by COVID-19 and other infectious disease testing capabilities. Their proprietary bioinformatics platform and flexible test menu design enable rapid addition of new NGS panels in response to evolving clinical needs. Fulgent's combination of technology-enabled testing economics, broad clinical application coverage, and growing biopharma services business supports their expansion as a diversified clinical genomics and sequencing services provider.

30. SD Biosensor, Inc.

SD Biosensor, Inc. is a South Korean in vitro diagnostics company with growing capabilities in molecular diagnostics that intersect with next-generation sequencing and advanced nucleic acid detection technologies. Their expertise in rapid diagnostic test development and manufacturing, combined with investments in molecular testing platforms, positions SD Biosensor as an emerging participant in the broader nucleic acid testing and genomics diagnostics ecosystem. SD Biosensor's established global distribution infrastructure and manufacturing scale provide a foundation for expanding their molecular and sequencing-adjacent diagnostics portfolio in both established and emerging healthcare markets.